drugset
drugset / Trial / NCT03795012

Trial With Eribulin or Eribulin+ Endocrine Therapy in Locally-recurrent or Metastatic Breast Cancer Patients

NCT03795012 ↗

Phase 2 Terminated 22 enrolled MedSIR
RandomizedParallel-groupOpen-labelTreatment

Summary

Unresectable, ER-positive and/or PR-positive and HER2-negative locally-recurrent or metastatic breast cancer (mBC).

Timeline

Start
2019-04-30
Primary completion
2021-03-31
Completion
2021-03-31

Drugs

EvaluationDrugModalityDoseRoute
Comparator Eribulin Small molecule — Intravenous

Indications

breast cancer